ALEXANDRIA, Va., Jan. 8, 2014 /PRNewswire/ -- Oxford Finance LLC ("Oxford"), a specialty finance firm that provides senior debt to life sciences and healthcare services companies, today announced that it entered into a term loan agreement with Entellus Medical, Inc. that expanded the original $17 million loan facility to $25 million. Entellus is using proceeds of the loan to support business operations and the ongoing marketing efforts for its minimally invasive treatments for chronic sinusitis.
"Entellus has impressed the medical community with its quality solutions for treating patients with sinusitis," said Christopher A. Herr, managing director for Oxford Finance. "We are pleased to provide financial support to the company as it continues to grow revenues and increase market share."
"Oxford has been a valued and reliable financial partner for Entellus," said Thomas E. Griffin, chief financial officer for Entellus Medical. "They understand our industry and support our primary business goal, which is to bring highly efficacious and cost-saving sinusitis treatments to patients in the convenience of the doctor's office."
About Oxford Finance LLC
Oxford Finance is a specialty finance firm providing senior secured loans to public and private life science and healthcare services companies worldwide. For over 20 years, Oxford has delivered flexible financing solutions to its clients, enabling these companies to maximize their equity by leveraging their assets. In recent years, Oxford has originated over $2 billion in loans, with lines of credit ranging from $500 thousand to $50 million. Oxford is headquartered in Alexandria, Virginia, with additional offices in California, Illinois, Massachusetts and North Carolina. For more information visit www.oxfordfinance.com.
About Entellus Medical, Inc.
Entellus Medical provides complete solutions for the minimally invasive treatment of chronic and recurrent sinusitis patients and is leading the way with easy-to-use, cost-effective products designed for office-based balloon dilation of narrowed sinus pathways. With this approach, Entellus sinus dilation products also provide significant efficiency and cost-effectiveness for sinus dilation procedures performed in operating rooms. For more information on XprESS™ Multi-Sinus Dilation Tool, FinESS™ Sinus Treatment, or PathAssist™ sinus confirmation tools visit www.EntellusMedical.com.
SOURCE Oxford Finance LLC